{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:54:58Z","timestamp":1792529698923,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004450.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T00:00:00Z","timestamp":1377043200000}}],"reference-count":221,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004450.pub3","type":"journal-article","created":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T08:15:36Z","timestamp":1377072936000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia"],"prefix":"10.1002","volume":"2013","author":[{"given":"Sheila A","family":"Fisher","sequence":"first","affiliation":[{"name":"NHS Blood and Transplant; Systematic Review Initiative; Level 2, John Radcliffe Hospital Headington Oxford Oxon UK OX3 9BQ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J","family":"Brunskill","sequence":"additional","affiliation":[{"name":"NHS Blood and Transplant; Systematic Review Initiative; Level 2, John Radcliffe Hospital Headington Oxford Oxon UK OX3 9BQ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Doree","sequence":"additional","affiliation":[{"name":"NHS Blood and Transplant; Systematic Review Initiative; Level 2, John Radcliffe Hospital Headington Oxford Oxon UK OX3 9BQ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gooding","sequence":"additional","affiliation":[{"name":"John Radcliffe and Churchill Hospital; Department of Haematology; Old Road Oxford UK OX3 7LJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onima","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Weatherall Institute of Molecular Medicine; Haematopoietic Stem Cell Laboratory; John Radcliffe and Churchill Hospital Oxford UK OX3 9DS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Roberts","sequence":"additional","affiliation":[{"name":"NHS Blood and Transplant; Systematic Review Initiative; Level 2, John Radcliffe Hospital Headington Oxford Oxon UK OX3 9BQ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,8,21]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD004450.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/10245330701521614","article-title":"Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience","volume":"12","author":"Abdelrazik","year":"2007","journal-title":"Hematology"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0002|cit2","first-page":"Abstract no: 11","article-title":"Pattern of iron chelation therapy in Egyptian children with beta-thalassaemia: one-year Mansoura University Childrens Hospital experience [abstract]","volume":"92 Suppl 1","author":"Abdelrazik","year":"2007","journal-title":"Haematologica"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD004450.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1182\/blood.V106.11.2698.2698","article-title":"Randomised, prospective evaluation of iron balance, chelation efficiency, urine excretion and NTBI progression with deferiprone (DFP) or deferoxamine (DFO) monotherapy or with combined DFP plus DFO [abstract]","volume":"106","author":"Aydinok","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD004450.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"Abstract no: 55","DOI":"10.1182\/blood.V108.11.557.557","article-title":"A randomized controlled trial comparing the combination therapy of deferiprone (DFP) and desferrioxamine (DFO) versus DFP or DFO monotherapy in patients with thalassaemia major [abstract]","volume":"108","author":"Aydinok","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD004450.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.11414","article-title":"A randomized, controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassaemia major","volume":"92","author":"Aydinok","year":"2007","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0006|cit6","first-page":"Abstract no: 51","article-title":"A randomized, controlled, prospective clinical study comparing the combination therapy of deferiprone (L1) and desferrioxamine (DFO) with L1 and DFO monotherapy in patients with thalassaemia major [abstract]","volume":"91","author":"Manz","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0022-3476(97)70314-7","article-title":"Evaluation of a new method of administration of the iron chelating agent deferoxamine","volume":"130","author":"Borgna-Pignatti","year":"1997","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Brissot P Turlin B Forni GL Alimena G Quarta G Selleslag D Iron chelation therapy with deferasirox (Exjade, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion-dependent anemia [abstract] Blood 2005 Abstract no: 823","DOI":"10.1182\/blood.V106.11.823.823"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Cappellini M Bejaoui M Perrotta S Agaoglu L Kattamis A Giardina P Phase III evaluation of once-daily, oral therapy with ICL670 (Exjade) versus deferoxamine in patients with beta-thalassaemia and transfusional hemosiderosis [abstract] Blood 2004 Abstract no: 3619","DOI":"10.1182\/blood.V104.11.3619.3619"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"Abstract no: 27","DOI":"10.1182\/blood.V106.11.2704.2704","article-title":"Patient satisfaction with desferasirox (Exjade ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy [abstract]","volume":"106","author":"Cappellini","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD004450.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.clinthera.2007.05.007","article-title":"Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia","volume":"29","author":"Cappellini","year":"2007","journal-title":"Clinical Therapeutics"},{"issue":"9","key":"10.1002\/14651858.CD004450.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"A phase 3 study of deferasirox (ICL670), a once daily oral iron chelator in patients with beta-thalassaemia","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/blood-2007-08-109306","article-title":"Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia-major","volume":"111","author":"Cohen","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1196\/annals.1345.021","article-title":"Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassaemia patients with transfusional iron overload","volume":"1054","author":"Galanello","year":"2005","journal-title":"Annals of New York Academy of Science"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"Abstract no: 26","DOI":"10.1182\/blood.V106.11.2692.2692","article-title":"Deferasirox (Exjade, ICL 670) demonstrates iron chelating efficacy related to transfusional iron intake in pediatric patients [abstract]","volume":"106","author":"Kattamis","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0016|cit16","first-page":"Abstract no: 20","article-title":"Evaluation of myocardial deposition assessed with MRI in young thalassaemia patients receiving one year of deferasirox versus deferoxamine [abstract]","volume":"91","author":"Christoforidis","year":"2006","journal-title":"Haematologica"},{"issue":"7","key":"10.1002\/14651858.CD004450.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00277-008-0471-2","article-title":"Iron chelation in thalassaemia: combined or monotherapy? The Egyptian experience","volume":"87","author":"El-Beshlawy","year":"2008","journal-title":"Annals of Hematology"},{"issue":"9","key":"10.1002\/14651858.CD004450.pub3-BIB0018|cit18","first-page":"1241","article-title":"A prospective randomised controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassaemia","volume":"91","author":"Galanello","year":"2006","journal-title":"Haematologica"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD004450.pub3-BIB0019|cit19","first-page":"Abstract no: 36","article-title":"Safety and efficacy of alternate desferrioxamine and deferiprone compared to desferrioxamine alone in the treatment of iron overload in transfusion-dependent thalassemia patients [abstract]","volume":"104","author":"Galanello","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0020|cit20","first-page":"21","article-title":"Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassaemic children","volume":"41","author":"Gomber","year":"2004","journal-title":"Indian Paediatrics"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/03630260600642617","article-title":"A randomised controlled study evaluating the safety and efficacy of deferiprone treatment in thalassaemia major patients from Hong Kong","volume":"30","author":"Ha","year":"2006","journal-title":"Hemoglobin"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0022|cit22","unstructured":"Ha SY Chik KW Ling SC Lee ACW A randomised controlled study on safety and efficacy of iron chelation therapy with (L1) deferiprone in thalassaemic major patients [abstract] Conference proceedings for the 13th International Conference on Oral Chelation in the treatment of thalassaemia and other diseases 2003 Abstract no: 72"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/03630260600642617","article-title":"A randomised controlled study evaluating the safety and efficacy of deferiprone treatment in thalassaemia major patients from Hong Kong","volume":"30","author":"Ha","year":"2006","journal-title":"Hemoglobin"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0024|cit24","unstructured":"Ha SY Chik KW Ling SC Lee ACW A randomised controlled study on safety and efficacy of iron chelation therapy with (L1) deferiprone in thalassaemic major patients [abstract] Conference Proceedings for the 13th International Conference on Oral Chelation in the Treatment of Thalassaemia and Other Diseases 2003 Abstract no: 72"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1081\/HEM-120021538","article-title":"Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with deferoxamine or deferiprone during a randomized multicenter prospective clinical study","volume":"27","author":"Galia","year":"2003","journal-title":"Hemoglobin"},{"issue":"10 Suppl 1 Pt 2","key":"10.1002\/14651858.CD004450.pub3-BIB0026|cit26","first-page":"34b","article-title":"Evaluation of efficacy of L1 versus desferrioxamine by clinical randomized multicentric study [abstract]","volume":"94","author":"Maggio","year":"1999","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/bcmd.2002.0510","article-title":"Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial","volume":"28","author":"Maggio","year":"2002","journal-title":"Blood Cells, Molecules and Diseases"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"Abstract no: 38","DOI":"10.1182\/blood.V112.11.3885.3885","article-title":"Decrease of mortality during deferiprone treatments: results from a large randomised cohort of thalassemia major patients under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies [abstract]","volume":"112","author":"Maggio","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD004450.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bcmd.2009.01.002","article-title":"Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies","volume":"42","author":"Maggio","year":"2009","journal-title":"Blood Cells, Molecules and Diseases"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2009.07609.x","article-title":"Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial","volume":"145","author":"Maggio","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD004450.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/03630269.2011.570674","article-title":"Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in beta-thalassemia major patients","volume":"35","author":"Pantalone","year":"2011","journal-title":"Hemoglobin"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.04240.x","article-title":"Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients","volume":"121","author":"Mourad","year":"2003","journal-title":"British Journal of Haematology"},{"issue":"8726","key":"10.1002\/14651858.CD004450.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/0140-6736(90)92962-H","article-title":"Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients","volume":"336","author":"Olivieri","year":"1990","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0034|cit34","first-page":"101","article-title":"Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients","volume":"27","author":"Olivieri","year":"1990","journal-title":"Seminars in Hematology"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1749-6632.1990.tb24324.x","article-title":"Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients","volume":"612","author":"Olivieri","year":"1990","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0036|cit36","unstructured":"ApoPharma Inc Oncologic drugs advisory committee briefing document: NDA #21-825 US Food and Drug Administration 2011 100-101 (http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/ucm271469.htm)"},{"issue":"10 Suppl 1 Pt 2","key":"10.1002\/14651858.CD004450.pub3-BIB0038|cit37","first-page":"35b","article-title":"Evidence of progression of myocardial iron loading as determined by magnetic resonance imaging (MRI) in thalassemia patients during treatment with deferiprone (L1) and deferoxamine (DFO) [abstract]","volume":"94","author":"Olivieri","year":"1999","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0039|cit38","first-page":"264a","article-title":"Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO) [abstract]","volume":"90","author":"Olivieri","year":"1997","journal-title":"Blood"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD004450.pub3-BIB0037|cit39","first-page":"249a","article-title":"First prospective randomized trial of the iron chelators deferiprone (L1) and deferoxamine [abstract]","volume":"86","author":"Olivieri","year":"1995","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD004450.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","article-title":"Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis","volume":"107","author":"Pennell","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1532-429X-13-34","article-title":"Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload","volume":"13","author":"Smith","year":"2011","journal-title":"Journal of Cardiovascular Magnetic Resonance"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0042|cit42","unstructured":"Cappellini MD Galanello R Piga A Forni GL Opitz H Ford JM Pharmacokinetics (PK) profile of the new oral iron chelator ICL670 after 6 months of treatment in a Phase II study in patients with transfusional hemosiderosis [abstract] Proceedings of the 8th Congress of the European Haematology Association 2003 Abstract no: 0909"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0043|cit43","unstructured":"Cappellini MD Galanello R Piga A Forni GL Zanaboni L Muroni P Update on the effects of ICL670, a novel tridentate oral iron chelator on liver iron concentration in patients with transfusion dependent iron overload [abstract] Haematology Journal 2002 Abstract no: 0610"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0044|cit44","unstructured":"Piga A Galanello R Cappelli MD Forni GL Lupo G Ford JM Phase II study of ICL670, an oral iron chelator in adult thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 18 months of therapy [abstract] Blood 2003 Abstract no: 412"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0045|cit45","first-page":"Abstract no: 5a","article-title":"Phase II study of oral chelator ICL670 in thalassamia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy [abstract]","volume":"100","author":"Piga","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD004450.pub3-BIB0046|cit46","first-page":"873","article-title":"Randomised phase II trial of deferasirox (Exjade ICL670), a once daily, orally administered iron chelator, in comparison to deferoxamine in thalassaemia patients with transfusional iron overload","volume":"91","author":"Piga","year":"2006","journal-title":"Haematologica"},{"issue":"6","key":"10.1002\/14651858.CD004450.pub3-BIB0047|cit47","first-page":"655","article-title":"Comparison between deferoxamine and combined therapy with deferoxamine and deferiprone in iron overloaded thalassemia patients","volume":"12","author":"Tamaddoni","year":"2010","journal-title":"Iranian Red Crescent Medical Journal"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0048|cit48","unstructured":"Alpendurada F Carpenter JP Smith GC Tanner MA Banya W Galanello R Effect of myocardial iron removal on right ventricular function: insights from a randomized, placebo controlled, double blind trial in thalassemia major [abstract] European Heart Journal; Proceedings of the European Society of Cardiology, ESC Congress, Stockholm, Sweden 2010"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"Abstract no: 36","DOI":"10.1182\/blood.V106.11.3600.3600","article-title":"Improved myocardial T2* in transfusion dependent anemias receiving ICL670 (Deferasirox) [abstract]","volume":"106","author":"Porter","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0050|cit50","doi-asserted-by":"crossref","unstructured":"Tanner M The effect of combined therapy with deferoxamine and deferiprone on myocardial iron and endothelial function in thalassaemia major: a randomised controlled trial using cardiovascular magnetic resonance [abstract] Proceedings of the European Haematology Association 11th Congress 2006 Abstract no: 0517","DOI":"10.1182\/blood.V106.11.3655.3655"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"Abstract no: 17","DOI":"10.1182\/blood.V108.11.1770.1770","article-title":"Improved endothelial function with combined chelation therapy in thalassaemia major [abstract]","volume":"108","author":"Tanner","year":"2006","journal-title":"Blood"},{"issue":"14","key":"10.1002\/14651858.CD004450.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","article-title":"A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance","volume":"115","author":"Tanner","year":"2007","journal-title":"Circulation"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD004450.pub3-BIB0053|cit53","first-page":"Abstract no: 36","article-title":"A randomized, placebo controlled double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance [abstract]","volume":"106","author":"Tanner","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0054|cit54","first-page":"11","article-title":"Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion","volume":"28","author":"Yarali","year":"2006","journal-title":"Journal of Pediatric Hematology and Oncology"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0055|cit55","unstructured":"Agouzal M Quyou A Practice of iron chelation in the therapeutic center of thalassemia in Morocco Vox Sanguinis: 31st International Congress of the International Society of Blood Transfusion in Joint Cooperation with the 43rd Congress of the DGTI, Berlin, Germany 2010"},{"issue":"3","key":"10.1002\/14651858.CD004450.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000205046","article-title":"High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation","volume":"84","author":"Aldouri","year":"1990","journal-title":"Acta Haematologica"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2141.1992.tb06441.x","article-title":"Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1","volume":"82","author":"Al-Refaie","year":"1992","journal-title":"British Journal of Haematology"},{"issue":"9332","key":"10.1002\/14651858.CD004450.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(02)09740-4","article-title":"Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia","volume":"360","author":"Anderson","year":"2002","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD004450.pub3-BIB0059|cit59","first-page":"273","article-title":"On the treatment of iron overload with the iron chelating agent Desferrioxamine (Desferal)","volume":"35","author":"Andres","year":"1980","journal-title":"Dt. Gesundh-Wesen"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0060|cit60","unstructured":"Athanassiou-Metaxa M Kousi A Hatzipantelis E Tsatra I Ikonomou M Perifanis V Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded \u00df-thalassemia patients Haematologica 2004 ELT07"},{"issue":"909","key":"10.1002\/14651858.CD004450.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/bmj.2.5909.16","article-title":"Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology and clinical progress","volume":"2","author":"Barry","year":"1974","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1136\/bmj.284.6322.1081","article-title":"Survival and deferioxamine in thalassaemia major","volume":"284","author":"Modell","year":"1982","journal-title":"British Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/10245332.1999.11746432","article-title":"Erythropoiesis: comparison of cytotoxic aldehyde generation in beta-thalassaemia patients chelated with deferoxamine or deferiprone (L1) versus no chelation","volume":"4","author":"Bartfay","year":"1999","journal-title":"Haematology"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0064|cit64","first-page":"27","article-title":"Survival in thalassaemia with conventional treatment","volume":"309","author":"Borgna-Pignatti","year":"1989","journal-title":"Progress in Clinical and Biological Research"},{"issue":"9","key":"10.1002\/14651858.CD004450.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM199409013310902","article-title":"Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassaemia major","volume":"331","author":"Brittenham","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD004450.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJM199009133231104","article-title":"Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassaemia major","volume":"323","author":"Bronspiegel-Weintrob","year":"1990","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1749-6632.1998.tb10524.x","article-title":"Survival and morbidity in transfusion-dependent thalassaemic patients on subcutaneous desferrioxamine chelation. Nearly two decades of experience","volume":"850","author":"Calleja","year":"1998","journal-title":"Annals New York Academy of Science"},{"issue":"9","key":"10.1002\/14651858.CD004450.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00277-012-1480-8","article-title":"Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients","volume":"91","author":"Cassinerio","year":"2012","journal-title":"Annals of Hematology"},{"issue":"9","key":"10.1002\/14651858.CD004450.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/MPH.0b013e318142b51e","article-title":"Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone","volume":"29","author":"Christioforidis","year":"2007","journal-title":"Journal of Paediatric Haematology and Oncology"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0070|cit70","first-page":"5","article-title":"Intensive long-term intravenous iron-chelation therapy with deferoxamine in thalassaemic patients","volume":"12 Suppl 1","author":"Cianciulli","year":"1993","journal-title":"Bone Marrow Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/ki.1994.295","article-title":"Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy","volume":"46","author":"Cianciulli","year":"1994","journal-title":"Kidney International"},{"issue":"8343","key":"10.1002\/14651858.CD004450.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0140-6736(83)90170-8","article-title":"Ocular toxicity of high-dose intravenous desferrioxamine","volume":"2","author":"Davies","year":"1983","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD004450.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1365-2265.1994.tb02514.x","article-title":"Effect of different treatment regimes on linear growth and final height in beta-thalassaemia major","volume":"40","author":"Sanctis","year":"1994","journal-title":"Clinical Endocrinology"},{"issue":"4","key":"10.1002\/14651858.CD004450.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0022-3476(88)80375-5","article-title":"Deferoxamine-induced growth retardation in patients with thalassaemia major","volume":"113","author":"DeVirgiliis","year":"1988","journal-title":"Journal of Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/03630260903546445","article-title":"Deferoxamine versus combined therapy for chelating liver, spleen and bone marrow iron in beta-thalassemic patients: a quantitative magnetic resonance imaging study","volume":"34","author":"Drakonaki","year":"2010","journal-title":"Hemoglobin"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"Abstract no: 37","DOI":"10.1182\/blood.V108.11.3732.3732","article-title":"Liver status in a cohort of polytransfused b-thalasseamie major (BTM) on long term desferrioxamine (DFO) or Deferiprone (L1) [abstract]","volume":"108","author":"Elalfy","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0077|cit77","first-page":"Abstract no: 36","article-title":"Response of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anaemias: a subgroup analysis [abstract]","volume":"91 Suppl 1","author":"Eleftherioiu","year":"2006","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"Abstract no: 36","DOI":"10.1182\/blood.V106.11.3600.3600","article-title":"Improved myocardial mT2* in transfusion dependent anemias receiving ICL670 (Deferasirox) [abstract]","volume":"106","author":"Porter","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0079|cit79","first-page":"299, Abstract n","article-title":"Cardiac function in thalassaemics on combined deferoxamine and deferiprone therapy [abstract]","volume":"92","author":"Fragatou","year":"2007","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0080|cit80","first-page":"32b","article-title":"A depot formulation of desferrioxamine (ICL749B): update on the dose-finding program [abstract]","volume":"94","author":"Galanello","year":"1999","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD004450.pub3-BIB0081|cit81","first-page":"300","article-title":"Intravenous chelation therapy during transplantation for thalassaemia","volume":"80","author":"Gaziev","year":"1995","journal-title":"Haematologica"},{"issue":"3","key":"10.1002\/14651858.CD004450.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1472-8206.2009.00681.x","article-title":"Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial","volume":"23","author":"Gharagozloo","year":"2009","journal-title":"Fundamental and Clinical Pharmacology"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0083|cit83","doi-asserted-by":"crossref","unstructured":"Goulas V Kourakli-Symeonidis A Camoutisis C Comparative effects of three iron chelation therapies on the quality of life in Greek patients with homozygous transfusion-dependent beta-thalassemia http:\/\/www.hindawi.com\/isrn\/hematology\/2012\/139862\/cta\/","DOI":"10.5402\/2012\/139862"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD004450.pub3-BIB0084|cit84","first-page":"494a","article-title":"When deferiprone and desferrioxamine are combined iron excretion is enhanced [abstract]","volume":"98","author":"Grady","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD004450.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0022-3476(78)80315-1","article-title":"Chelation therapy in beta-thalassaemia major. I. Intravenous and subcutaneous deferoxamine","volume":"92","author":"Graziano","year":"1978","journal-title":"Journal of Pediatrics"},{"issue":"7998","key":"10.1002\/14651858.CD004450.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(76)92035-3","article-title":"Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload","volume":"2","author":"Hussain","year":"1976","journal-title":"Lancet"},{"issue":"8210","key":"10.1002\/14651858.CD004450.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(81)90165-3","article-title":"Oral desferrioxamine in young patients with thalassaemia","volume":"1","author":"Kattamis","year":"1981","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD004450.pub3-BIB0088|cit88","first-page":"1423","article-title":"Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion","volume":"88","author":"Kattamis","year":"2003","journal-title":"Haematologica"},{"issue":"8","key":"10.1002\/14651858.CD004450.pub3-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1111\/trf.12024","article-title":"Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent beta-thalassemia patients","volume":"53","author":"Keshtharan","year":"2013","journal-title":"Transfusion"},{"issue":"6612","key":"10.1002\/14651858.CD004450.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1136\/bmj.295.6612.1509","article-title":"Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.","volume":"295","author":"Kontoghiorghes","year":"1987","journal-title":"British Medical Journal (Clinical Research Edition)"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bcmd.2010.05.005","article-title":"Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to deferoxamine alone","volume":"45","author":"Lai","year":"2010","journal-title":"Blood Cells, Molecules and Diseases"},{"issue":"6","key":"10.1002\/14651858.CD004450.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/sj.bmt.1702212","article-title":"Early iron reduction programme for thalassaemia patients after bone marrow transplantation","volume":"25","author":"Li","year":"2000","journal-title":"Bone Marrow Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD004450.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1046\/j.1365-2141.1997.2463064.x","article-title":"Immune function in patients with beta-thalassamia receiving the orally active iron-chelating agent deferiprone","volume":"98","author":"Loebstein","year":"1997","journal-title":"British Journal of Haematology"},{"issue":"8","key":"10.1002\/14651858.CD004450.pub3-BIB0094|cit94","first-page":"177","article-title":"Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload","volume":"12","author":"Nienhuis","year":"1976","journal-title":"Birth Defects: Original Article Series"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ajh.2830410112","article-title":"Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine","volume":"41","author":"Olivieri","year":"1992","journal-title":"American Journal of Haematology"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0096|cit96","first-page":"20-61, Abstract","article-title":"Deferirpone in patients with beta-thalassamiea major for 4 years in the Chinese population in Taiwan [abstract]","volume":"34 Suppl 1","author":"Peng","year":"2004","journal-title":"European Journal of Clinical Investigation"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0097|cit97","first-page":"Abstract no: 37","article-title":"Study of deferiprone or deferoxamine versus combination therapy in iron-loaded thalassaemia patients in Taiwan [abstract]","volume":"18","author":"Peng","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0098|cit98","doi-asserted-by":"crossref","unstructured":"Pennell D Porter JB Cappellini MD Chan L El-Beshlawi A Aydinok Y Continued improvement and normalization of myocardial T2* in patients with beta-thalassemia major treated with deferasirox (Exjade) for up to 3 years Blood 2010","DOI":"10.1182\/blood.V116.21.4276.4276"},{"issue":"6","key":"10.1002\/14651858.CD004450.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3324\/haematol.2011.049957","article-title":"Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with beta-thalassemia major","volume":"97","author":"Pennell","year":"2012","journal-title":"Haematologica"},{"issue":"3","key":"10.1002\/14651858.CD004450.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1600-0609.2005.00587.x","article-title":"Evaluation of the efficacy of oral deferiprone in beta-thalassaemia major by multislice multiecho T2*","volume":"76","author":"Pepe","year":"2006","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"Abstract no: 27","DOI":"10.1182\/blood.V110.11.2774.2774","article-title":"Long-term efficacy and safety with Deferasirox (Exjade ICL670) a once-daily oral iron chelator in pediatric patients [abstract]","volume":"110","author":"Piga","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0102|cit102","first-page":"99","article-title":"Intensive iron-chelation therapy with desferrioxamine in iron-loading anaemias","volume":"54","author":"Pippard","year":"1978","journal-title":"Clinical Science and Molecular Medicine"},{"issue":"8","key":"10.1002\/14651858.CD004450.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1056\/NEJM197708252970804","article-title":"Continuous subcutaneous administration of deferoxamine in patients with iron overload","volume":"297","author":"Propper","year":"1977","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1600-0609.2010.01447.x","article-title":"Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study","volume":"85","author":"Ricchi","year":"2010","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0105|cit105","first-page":"848","article-title":"Iron chelating therapy in thalassaemia: current problems","volume":"75 Suppl 5","author":"Russo","year":"1990","journal-title":"Haematologica"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1034\/j.1600-0609.2001.067001030.x","article-title":"Comparison between deferoxamine and deferiprone (L1) in iron-loaded patients","volume":"67","author":"Taher","year":"2001","journal-title":"European Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1532-429X-10-12","article-title":"Combined chelation therapy in thalassaemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction","volume":"10","author":"Tanner","year":"2008","journal-title":"Journal of Cardiovascular Magnetic Resonance"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0108|cit108","first-page":"96","article-title":"High transfusion in children with beta-thalassaemia\/Hb E: clinical and laboratory assessment of 18 cases","volume":"24 Suppl 1","author":"Torcharus","year":"1993","journal-title":"Southeast Asian Journal of Tropical Medicine and Public Health"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1079-9796(03)00206-7","article-title":"Deferiprone versus deferoxamine in patients with thalassaemia major: a randomized clinical trial","volume":"32","author":"Tsakok","year":"2004","journal-title":"Blood Cells, Molecules and Diseases"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0110|cit110","first-page":"23","article-title":"Pituitary function in thalassemic patients and the effect of chelation therapy","volume":"124","author":"Vannasaeng","year":"1991","journal-title":"Acta Endocrinologica (Copenh)"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0111|cit111","first-page":"Abstract no: 10","article-title":"Progenitor haemopoietic cells in the peripheral blood of thalassemic patients with desferrioxamine or deferiprone chelation therapy [abstract]","volume":"90 Suppl 2","author":"Vlachaki","year":"2005","journal-title":"Hematology"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1600-0609.2006.00773.x","article-title":"Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy","volume":"78","author":"Vlachaki","year":"2007","journal-title":"European Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD004450.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3324\/haematol.11755","article-title":"Inflamation and oxidant stress in beta-thalassaemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of Novartis CICL670A0107","volume":"93","author":"Walter","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/03630260600642609","article-title":"Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassaemia major patients","volume":"30","author":"Wang","year":"2006","journal-title":"Hemoglobin"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1046\/j.1365-2141.1998.01002.x","article-title":"Combined therapy with deferiprone and desferrioxamine","volume":"103","author":"Wonke","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"5","key":"10.1002\/14651858.CD004450.pub3-BIB0116|cit116","first-page":"488","article-title":"Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia","volume":"12","author":"Zareifar","year":"2009","journal-title":"Archives of Iranian Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1532-429X-14-8","article-title":"Effects of combined deferiprone with deferoxamine on right ventricular function in thalassemia major","volume":"14","author":"Alpendurada","year":"2012","journal-title":"Journal of Cardiovascular Magnetic Resonance"},{"issue":"21","key":"10.1002\/14651858.CD004450.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"Abstract no: 51","DOI":"10.1182\/blood.V116.21.5158.5158","article-title":"Probing the origin of chelatable iron during deferiprone and combination therapies: insights from plasma NTBI and LPI determinations [abstract]","volume":"116","author":"Aydinok","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD004450.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3324\/haematol.2011.056317","article-title":"Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response","volume":"97","author":"Aydinok","year":"2012","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0120|cit120","unstructured":"Badawy S Hassan TH Hesham MAA Badr MA Evaluation of iron chelation therapy in beta-thalassemic patients in Zagazig University Hospital Pediatric Blood and Cancer; Proceedings of the 23rd Annual Meeting of the American Society of Pediatric Hematology\/Oncology, ASPHO, Montreal, Canada 2010 799-800, Poster no: 124"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0121|cit121","first-page":"701, Abstract n","article-title":"Evaluation of iron chelation therapy in beta-thalassemia major patients in East Delta of Egypt","volume":"95 Suppl 2","author":"Hassan","year":"2010","journal-title":"Haematologica"},{"issue":"5","key":"10.1002\/14651858.CD004450.pub3-BIB0122|cit122","first-page":"550","article-title":"Continuous desferrioxamine infusion by an infusor in thalassaemia major","volume":"88","author":"Canatan","year":"1999","journal-title":"Acta Paediatrica"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0123|cit123","first-page":"9: E84","article-title":"Origin of chelatable iron during deferiprone and combination therapies: Insights from plasma NTBI and LPI","volume":"86","author":"Evans","year":"2011","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0124|cit124","first-page":"46","article-title":"A prospective study for determination of the mean red cell transfusion requirement compared on the basis of iron overload and type of chelation therapy in multiply transfused thalassaemia major patients","volume":"21","author":"Jain","year":"2011","journal-title":"Transfusion Medicine. 29th Annual Scientific Meeting of the British Blood Tranfusion Society, Glasgow, UK"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0125|cit125","first-page":"21","article-title":"Comparative efficacy of deferrioxamine and combination of deferiprone and deferrioxamine on echocardiographic indices in beta thalassemic patients","volume":"14","author":"Kompany","year":"2009","journal-title":"Scientific Journal of Kurdistan University of Medical Sciences"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0126|cit126","unstructured":"Maggio A Capra M Cuccia L Gagliardotto F Rigano P Calvaruso G Long-term use of deferiprone enhances significantly the left ventricular ejection function in thalassemia major [abstract] ASH Annual Meeting Abstracts; 53rd American Society of Hematology (ASH) Annual Meeting, 10-13 December 2011, San Diego, USA 2011 21; Abstract no: 5302"},{"issue":"7","key":"10.1002\/14651858.CD004450.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.23219","article-title":"Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalssemia major patients","volume":"87","author":"Maggio","year":"2012","journal-title":"American Journal of Hematology"},{"issue":"3","key":"10.1002\/14651858.CD004450.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1179\/102453312X13376952196610","article-title":"The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients","volume":"17","author":"Mirbehbahani","year":"2012","journal-title":"Hematology"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0129|cit129","unstructured":"N0277104959 A randomised controlled prospective trial using Ferriprox versus placebo and conventional intravenous and subcutaneous iron chelation http:\/\/www.nihr.ac.uk\/Profile\/Pages\/NRRResults.aspx?publication_id=N0277104959"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0130|cit130","unstructured":"NCT00004982 Combination Iron Chelation Therapy http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00004982?term=NCT00004982&rank=1"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0131|cit131","unstructured":"NCT00115349 Combination therapy compared with single-drug therapy in patients with cardiac diseases http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00115349?term=NCT00115349&rank=1"},{"issue":"3","key":"10.1002\/14651858.CD004450.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/03630269.2011.570674","article-title":"Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: Main findings and clinical follow-up of a large multicenter randomized clinical trial in beta-thalassemia major patients","volume":"35","author":"Pantalone","year":"2011","journal-title":"Hemoglobin"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0133|cit133","unstructured":"Pennell D Porter J Piga A El-Alfy M El-Beshlawi A Kilinc Y Prevalence of cardiac iron overload in patients with transfusion-dependent anemias: data from the ranodomized, active-controlled deferasirox CORDELIA trial Haematologica. 17th Congress of the European Hematology Assocation, Amsterdam, The Netherlands, 14-17 June 2012 2012 Abstract no: 0927"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0134|cit134","doi-asserted-by":"crossref","unstructured":"Pennell DJ Porter JB Piga A Lai Y El-Beshlawi A Beloul K A multicenter, randomized, open-label trial evaluating deferasirox compared with deferoxamine for the removal of cardiac iron in patients with beta-thalassemia major and iron overload (CORDELIA) Blood 2012","DOI":"10.1182\/blood.V120.21.2124.2124"},{"issue":"21","key":"10.1002\/14651858.CD004450.pub3-BIB0135|cit135","first-page":"Abstract","article-title":"Prospective comparison on cardiac and hepatic iron and cardiac function by MR in thalassemia major patients treated with combination deferiprone-desferrioxamine versus deferiprone and desferrioxamine in monotherapy [abstract]","volume":"118","author":"Pepe","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0136|cit136","doi-asserted-by":"crossref","unstructured":"Pepe A Meloni A Rossi G Cuccia L D'Ascola GD Santodirocco M Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy http:\/\/www.jcmr-online.com\/content\/pdf\/1532-429X-15-1.pdf 10.1186\/1532-429X-15-1","DOI":"10.1186\/1532-429X-15-1"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0137|cit137","first-page":"805","article-title":"Cardiac iron and function by CMR in thalassemia major patients treated with combined deferiprone and desferrioxamine regimen versus montherapies: a multi-center, observational and prospective study","volume":"33","author":"Pepe","year":"2012","journal-title":"European Heart Journal"},{"issue":"21","key":"10.1002\/14651858.CD004450.pub3-BIB0138|cit138","first-page":"Abstract no: 51","article-title":"Prospective comparison on cardiac iron and liver iron by MR in thalassemia major patients treated with combination deferiprone-desferrioxamine versus deferiprone and desferrioxamine in monotherapy [abstract]","volume":"116","author":"Pepe","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0139|cit139","first-page":"696, Abstract n","article-title":"Prospective comparison on cardiac iron and liver iron by MR in thalassemia major patients treated with combination deferiprone-desferrioxamine versus deferiprone and desferrioxamine in monotherapy [abstract]","volume":"95 Suppl 2","author":"Pepe","year":"2010","journal-title":"Haematologica, Proceedings of the 15th Congress of the European Hematology Association, Barcelona, Spain"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0140|cit140","first-page":"514-5, Abstract","article-title":"The cardiac effects of desferoxamine deferiprone combination therapy and desferoxamine monotherapy in thalassemic patients [abstract]","volume":"94 Suppl 2","author":"Unal","year":"2009","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0141|cit141","unstructured":"IRCT20110087677N1 The comparative study of incidence of lens opacity between Osfereal and Deferoxamine in major thalassemia http:\/\/apps.who.int\/trialsearch\/trial.aspx?trialid=IRCT201110087677N1"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0142|cit142","unstructured":"IRCT201206289827N2 Comparison of two methods of administration of deferoxamine (intravenous and subcutaneous) in terms of impact on reducing iron overload in thalassemia patients who have suffered heart failure http:\/\/apps.who.int\/trialsearch\/trial.aspx?trialid=IRCT201206289827N2"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0143|cit143","unstructured":"NCT01511848 Study of efficacy, safety of combined deferasirox and deferiprone versus combined deferiprone and desferal in conditions of iron overload http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01511848?term=NCT01511848&rank=1"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2141.1992.tb06445.x","article-title":"Long term assessment of efficacy and safety of L1, an oral iron chelator in transfusion-dependent thalassaemia: Indian trial","volume":"82","author":"Agarwal","year":"1992","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00330-002-1421-3","article-title":"MRI of the liver and the pituitary gland in patients with beta-thalassemia major: does hepatic siderosis predict pituitary iron deposition?","volume":"13","author":"Argyropoulou","year":"2003","journal-title":"European Radiology"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000040962","article-title":"Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey","volume":"102","author":"Aydinok","year":"1999","journal-title":"Acta Haematologica"},{"issue":"3","key":"10.1002\/14651858.CD004450.pub3-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1172\/JCI110787","article-title":"Hepatic lipid peroxidation in vivo in rats with chronic iron overload","volume":"71","author":"Bacon","year":"1983","journal-title":"Journal of Clinical Investigation"},{"issue":"3","key":"10.1002\/14651858.CD004450.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0955-3886(00)00092-8","article-title":"The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1)","volume":"23","author":"Berdoukas","year":"2000","journal-title":"Transfusion Science"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0149|cit149","unstructured":"Joint Formulary Committee British National Formulary http:\/\/www.bnf.org"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1749-6632.1998.tb10479.x","article-title":"Survival and disease complications in thalassemia major","volume":"850","author":"Borgna-Pignatti","year":"1998","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"9","key":"10.1002\/14651858.CD004450.pub3-BIB0151|cit151","first-page":"788","article-title":"Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload","volume":"83","author":"Borgna-Pignatti","year":"1998","journal-title":"Haematologica"},{"issue":"8354","key":"10.1002\/14651858.CD004450.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(83)90785-7","article-title":"Rapid desensitisation for desferrioxamine anaphylactoid reaction","volume":"2","author":"Bousquet","year":"1983","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0153|cit153","first-page":"56a","article-title":"Desferrioxsamine use protects against heart disease and death from transfusional iron overload in thalassemia major [abstract]","volume":"Suppl","author":"Brittenham","year":"1988","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD004450.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM199409013310902","article-title":"Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major","volume":"331","author":"Brittenham","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD004450.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1182\/blood-2002-10-3173","article-title":"Deferiprone and hepatic fibrosis","volume":"101","author":"Brittenham","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1046\/j.1365-2141.2002.03554.x","article-title":"The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients","volume":"118","author":"Ceci","year":"2002","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1365-2141.2000.01866.x","article-title":"Safety profile of the oral iron chelator: a multicentre study","volume":"108","author":"Cohen","year":"2000","journal-title":"British Journal of Haematology"},{"issue":"5","key":"10.1002\/14651858.CD004450.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2002-10-3280","article-title":"Safety and effectiveness of long term therapy with the oral iron chelator deferiprone profile of the oral iron chelator: a multicentre study","volume":"102","author":"Cohen","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD004450.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.V95.4.1229.004k32_1229_1236","article-title":"Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia","volume":"95","author":"Davis","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD004450.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF01955263","article-title":"Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine","volume":"155","author":"Sanctis","year":"1996","journal-title":"European Journal of Paediatrics"},{"issue":"2-3","key":"10.1002\/14651858.CD004450.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000039759","article-title":"Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting","volume":"104","author":"Vecchio","year":"2000","journal-title":"Acta Haematologica"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD004450.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0022-3476(05)83374-8","article-title":"Prolonged survival in patients with beta-thalassemia major treated with desferrioxamine","volume":"118","author":"Ehlers","year":"1991","journal-title":"Journal of Paediatrics"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0164|cit164","unstructured":"European Medicines Agency (EMA) Exjade: EPAR http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/PIP_decision\/WC500116591.pdf"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0165|cit165","unstructured":"US Food Drug Administration Oncologic Drugs Advisory Committee Briefing Document NDA # 21-825: Ferriprox\u00ae (deferiprone) is an iron chelator indicated for the treatment of patients with transfusional iron overload when current chelation therapy is inadequate http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/UCM271537.pdf"},{"issue":"6","key":"10.1002\/14651858.CD004450.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1046\/j.1365-2141.2003.04297.x","article-title":"Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with thalassaemia major: applicability of SQUID biomagnetic liver susceptometry","volume":"121","author":"Fischer","year":"2003","journal-title":"British Journal of Haematology"},{"issue":"9","key":"10.1002\/14651858.CD004450.pub3-BIB0167|cit167","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004839.pub3","article-title":"Oral deferiprone for iron chelation in people with thalassaemia","author":"Fisher","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD004450.pub3-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood.V95.9.2776.009k26_2776_2779","article-title":"Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload","volume":"95","author":"Franchini","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD004450.pub3-BIB0169|cit169","first-page":"565","article-title":"Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions","volume":"144","author":"Freedman","year":"1990","journal-title":"American Journal of Diseases of Children"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000203853","article-title":"Results of long-term iron-chelating therapy","volume":"95","author":"Gabutti","year":"1996","journal-title":"Acta Haematologica"},{"issue":"3","key":"10.1002\/14651858.CD004450.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1365-2141.1998.00726.x","article-title":"Iron chelators for thalassaemia","volume":"101","author":"Hershko","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"11","key":"10.1002\/14651858.CD004450.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD004450.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0174|cit174","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011] The Cochrane Collaboration 2011"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/blood.V91.1.295","article-title":"Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients","volume":"91","author":"Hoffbrand","year":"1998","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD004450.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3109\/03630260903213231","article-title":"Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis ofiron\u00a0overload and in the ferrikinetics of normalization of the\u00a0iron\u00a0stores in thalassemia using the International Committee on Chelation deferiprone\/deferoxamine combination protocol","volume":"33","author":"Kolnagou","year":"2009","journal-title":"Hemoglobin"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2141.1990.tb07887.x","article-title":"Long term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-1 (L1), I: iron chelation and metabolic studies","volume":"76","author":"Kontoghiorghes","year":"1990","journal-title":"British Journal of Haematology"},{"issue":"9","key":"10.1002\/14651858.CD004450.pub3-BIB0178|cit178","first-page":"1077","article-title":"Acute changes in renal function associated with DFO therapy","volume":"143","author":"Koren","year":"1989","journal-title":"American Journal of Diseases of Children"},{"issue":"5","key":"10.1002\/14651858.CD004450.pub3-BIB0179|cit179","first-page":"371","article-title":"The effects of subcutaneous deferoxamine administration on renal function in thalassemia major","volume":"54","author":"Koren","year":"1991","journal-title":"International Journal of Hematology"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0180|cit180","first-page":"47","article-title":"Secondary iron overload","volume":"2001","author":"Kushner","year":"2001","journal-title":"Hematology \/ the Education Program of the American Society of Hematology. American Society of Hematology. Education Program"},{"issue":"4","key":"10.1002\/14651858.CD004450.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4038\/cmj.v47i4.3413","article-title":"Experience with the oral iron chelator deferiprone in transfusion-dependent children","volume":"47","author":"Lucas","year":"2002","journal-title":"Ceylon Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD004450.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2141.2007.06666.x","article-title":"Light and shadows in the iron chelation treatment of haematological diseases","volume":"138","author":"Maggio","year":"2007","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD004450.pub3-BIB0183|cit183","first-page":"496","article-title":"Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia","volume":"83","author":"Mazza","year":"1998","journal-title":"Haematologica"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"iii-iv, ix-xi,","DOI":"10.3310\/hta13010","article-title":"Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation","volume":"13","author":"McLeod","year":"2009","journal-title":"Health Technology Assessment"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0185|cit185","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007476.pub2","article-title":"Deferasirox for managing iron overload in people with thalassaemia","author":"Meerpohl","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8228","key":"10.1002\/14651858.CD004450.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(81)92227-3","article-title":"Rapid desenstitisation for desferrioxamine anaphylactic reaction (letter)","volume":"1","author":"Miller","year":"1981","journal-title":"Lancet"},{"issue":"9220","key":"10.1002\/14651858.CD004450.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(00)02357-6","article-title":"Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register","volume":"355","author":"Modell","year":"2000","journal-title":"Lancet"},{"issue":"17","key":"10.1002\/14651858.CD004450.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1056\/NEJMsb020394","article-title":"Academic freedom in clinical research","volume":"347","author":"Nathan","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD004450.pub3-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1182\/blood-2006-02-002394","article-title":"Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions","volume":"107","author":"Neufeld","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1749-6632.1974.tb20588.x","article-title":"Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassaemia major","volume":"232","author":"O'Brien","year":"1974","journal-title":"Annals New York Academy of Science"},{"issue":"9","key":"10.1002\/14651858.CD004450.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199409013310903","article-title":"Survival in medically treated patients with homozygous beta-thalassemia","volume":"331","author":"Olivieri","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD004450.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJM199504063321404","article-title":"Iron-chelation therapy with oral deferiprone in patients with thalassemia major","volume":"332","author":"Olivieri","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0193|cit193","first-page":"249a","article-title":"First prospective randomized trial of the iron chelators deferiprone and deferoxamine [abstract]","volume":"86 Suppl 1","author":"Olivieri","year":"1995","journal-title":"Blood"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0194|cit194","first-page":"264a","article-title":"Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO) [abstract]","volume":"90 Suppl 1","author":"Olivieri","year":"1997","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD004450.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V89.3.739","article-title":"Iron-chelating therapy and the treatment of thalassemia","volume":"89","author":"Olivieri","year":"1997","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD004450.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199808133390701","article-title":"Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major","volume":"339","author":"Olivieri","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM199907083410207","article-title":"The beta-thalassemias","volume":"341","author":"Olivieri","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004450.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1600-0609.1999.tb01888.x","article-title":"Deferiprone (L1) associated neutropenia in beta thalassaemia major: an Indian experience","volume":"63","author":"Pati","year":"1999","journal-title":"European Journal of Haematology"},{"issue":"8075","key":"10.1002\/14651858.CD004450.pub3-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(78)90968-6","article-title":"Prevention of iron loading in transfusion-dependent thalassaemia","volume":"1","author":"Pippard","year":"1978","journal-title":"Lancet"},{"issue":"8147","key":"10.1002\/14651858.CD004450.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(79)92175-5","article-title":"Iron absorption and loading in beta-thalassaemia intermedia","volume":"2","author":"Pippard","year":"1979","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0201|cit201","first-page":"2","article-title":"Oral iron chelation therapy for thalassaemia: an uncertain scene","volume":"111","author":"Pippard","year":"2000","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD004450.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood.V71.4.1124.1124","article-title":"The effect of erythroid hyperplasia on iron balance","volume":"71","author":"Pootrakul","year":"1988","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0950-3536(89)80027-7","article-title":"The toxic effects of desferrioxamine","volume":"2","author":"Porter","year":"1989","journal-title":"Balliere's Clinical Haematology"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/beha.2002.0214","article-title":"Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia","volume":"15","author":"Porter","year":"2002","journal-title":"Best Practice Research in Clinical Haematology"},{"issue":"26","key":"10.1002\/14651858.CD004450.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1056\/NEJM197606242942603","article-title":"Reassessment of the use of desferrioxamine B in iron overload","volume":"294","author":"Propper","year":"1976","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0206|cit206","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"6","key":"10.1002\/14651858.CD004450.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1445-5994.1993.tb04722.x","article-title":"Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major","volume":"23","author":"Richardson","year":"1993","journal-title":"Australian and New Zealand Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004450.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1128\/iai.47.3.774-779.1985","article-title":"Effects of iron and desferrioxamine on infections with Yersinia Enterocolitica","volume":"47","author":"Robins-Browne","year":"1985","journal-title":"Infection and Immunity"},{"issue":"2","key":"10.1002\/14651858.CD004450.pub3-BIB0209|cit209","first-page":"115","article-title":"Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1)","volume":"85","author":"Rombos","year":"2000","journal-title":"Haematologica"},{"issue":"8795","key":"10.1002\/14651858.CD004450.pub3-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/0140-6736(92)90598-W","article-title":"Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning","volume":"339","author":"Tenenbein","year":"1992","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD004450.pub3-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2141.1990.tb07915.x","article-title":"L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major","volume":"76","author":"Tondury","year":"1990","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD004450.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2141.1998.00725.x","article-title":"Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients","volume":"101","author":"Tondury","year":"1998","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD004450.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jme.2003.006577","article-title":"Introduction to the Olivieri symposium","volume":"30","author":"Viens","year":"2004","journal-title":"Journal of Medical Ethics"},{"issue":"5","key":"10.1002\/14651858.CD004450.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood-2002-01-0306","article-title":"Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalasssemia","volume":"100","author":"Wanless","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD004450.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.1969.tb01407.x","article-title":"The effect of ascorbic acid deficiency on desferrioxamine-induced urinary iron excretion","volume":"17","author":"Wapnick","year":"1969","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD004450.pub3-BIB0216|cit216","doi-asserted-by":"crossref","DOI":"10.1002\/9780470696705","volume-title":"The Thalassamia Syndromes","author":"Weatherall","year":"2001"},{"issue":"4","key":"10.1002\/14651858.CD004450.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/35066048","article-title":"Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias","volume":"2","author":"Weatherall","year":"2001","journal-title":"Nature Reviews. Genetics"},{"issue":"25","key":"10.1002\/14651858.CD004450.pub3-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM198506203122503","article-title":"Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major","volume":"312","author":"Wolfe","year":"1985","journal-title":"New England Journal of Medicine"},{"issue":"8653","key":"10.1002\/14651858.CD004450.pub3-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(89)90264-X","article-title":"Survival and causes of death in thalassemia major","volume":"2","author":"Zurlo","year":"1989","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD004450.pub3-BIB0220|cit220","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004450","article-title":"Desferrioxamine mesylate for managing transfusional iron overload in people with thalassaemia (Protocol)","author":"Roberts","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4. Art No. CD00","key":"10.1002\/14651858.CD004450.pub3-BIB0221|cit221","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004450.pub2","article-title":"Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia","author":"Roberts","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD004450.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T20:07:27Z","timestamp":1729454847000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004450.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,8,21]]},"references-count":221,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004450.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,21]]}}}